Type 2 diabetes - In type 2 diabetes, the best data comparing renin-angiotensin system inhibition with alternative therapy come from the Irbesartan Diabetic Nephropathy Trial (IDNT) and the Reduction of Endpoints in Non-Insulin-Dependent Diabetes Mellitus with the Angiotensin II Antagonist Losartan (RENAAL) trial [47, 48]: